Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshu capsule is a traditional Chinese medicine (TCM) herbal compound, primarily used in China for the treatment of biliary disorders such as chronic cholecystitis and gallstones. It is formulated as a Chinese herbal compound (CHC) and is currently being evaluated by the First People's Hospital of Hangzhou in a Phase 4 clinical trial (NCT04484870) to prevent the recurrence of choledocholithiasis (bile duct stones) following endoscopic retrograde cholangiopancreatography (ERCP). The drug acts as a cholagogue, promoting the secretion and excretion of bile, and possesses anti-inflammatory and analgesic properties. In clinical studies, it has demonstrated efficacy comparable to ursodeoxycholic acid (UDCA) in improving liver function and reducing stone recurrence rates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danshu capsule.